Suchergebnisse - "Cook, Gordon"

PubPharm (36)

1

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

2

Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma : A real-world multicentre UK retrospective analysis

enthalten in: British journal of haematology | 2023

von McMillan, A. | Basu, S. | Karunanithi, K. | +22

3

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

4

Optimizing the value of lenalidomide maintenance by extended genetic profiling : an analysis of 556 patients in the Myeloma XI trial

enthalten in: Blood | 2023

von Panopoulou, A. | Cairns, D. | Holroyd, A. | +13

CommentIn: Blood. 2023 Apr 6;141(14):1649-1650. - PMID 37022733

5

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

6

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma : MUKeight phase II randomised controlled trial results

enthalten in: Blood cancer journal | 2022

von Auner, H. | Brown, S. | Walker, K. | +9

7

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

enthalten in: British journal of haematology | 2022

von Chan, W. | Counsell, N. | de Tute, R. | +24

8

Ixazomib-lenalidomide-dexamethasone in routine clinical practice : effectiveness in relapsed/refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2021

von Hájek, R. | Minařík, J. | Straub, J. | +33

9

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15

10

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21